26 related articles for article (PubMed ID: 17912028)
1. Cumulative evidence for association between genetic polymorphisms and esophageal cancer susceptibility: A review with evidence from meta-analysis and genome-wide association studies.
Tian J; Liu C; Liu G; Zuo C; Chen H
Cancer Med; 2019 Mar; 8(3):1289-1305. PubMed ID: 30793520
[TBL] [Abstract][Full Text] [Related]
2. NDRG1 overexpression promotes the progression of esophageal squamous cell carcinoma through modulating Wnt signaling pathway.
Ai R; Sun Y; Guo Z; Wei W; Zhou L; Liu F; Hendricks DT; Xu Y; Zhao X
Cancer Biol Ther; 2016 Sep; 17(9):943-54. PubMed ID: 27414086
[TBL] [Abstract][Full Text] [Related]
3. Cyclin D1 expression predicts postoperative distant metastasis and survival in resectable esophageal squamous cell carcinoma.
Hou X; Liang RB; Wei JC; Xu Y; Fu JH; Luo RZ; He JH; Zhang LJ; Lin P; Yang HX
Oncotarget; 2016 May; 7(21):31088-96. PubMed ID: 27145270
[TBL] [Abstract][Full Text] [Related]
4. Pyruvate kinase, muscle isoform 2 promotes proliferation and insulin secretion of pancreatic β-cells via activating Wnt/CTNNB1 signaling.
Wang S; Yang Z; Gao Y; Li Q; Su Y; Wang Y; Zhang Y; Man H; Liu H
Int J Clin Exp Pathol; 2015; 8(11):14441-8. PubMed ID: 26823761
[TBL] [Abstract][Full Text] [Related]
5. Role of novel and GWAS originated PLCE1 genetic variants in susceptibility and prognosis of esophageal cancer patients in northern Indian population.
Umar M; Upadhyay R; Kumar S; Ghoshal UC; Mittal B
Tumour Biol; 2014 Nov; 35(11):11667-76. PubMed ID: 25139097
[TBL] [Abstract][Full Text] [Related]
6. Genetic variants of EGF and VEGF predict prognosis of patients with advanced esophageal squamous cell carcinoma.
Yang PW; Hsieh MS; Huang YC; Hsieh CY; Chiang TH; Lee JM
PLoS One; 2014; 9(6):e100326. PubMed ID: 24945674
[TBL] [Abstract][Full Text] [Related]
7. Cyclin D1 G870A polymorphism and risk of nasopharyngeal carcinoma: a meta-analysis.
Li M; Dai W; Zhou H
ScientificWorldJournal; 2013; 2013():689048. PubMed ID: 24222746
[TBL] [Abstract][Full Text] [Related]
8. Role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of esophageal carcinoma and the suggested mechanisms of action.
Xu Y; Sheng L; Mao W
Oncol Lett; 2013 Jan; 5(1):19-24. PubMed ID: 23255886
[TBL] [Abstract][Full Text] [Related]
9. Prediction of CCND1 amplification using plasma DNA as a prognostic marker in oesophageal squamous cell carcinoma.
Takeshita H; Ichikawa D; Komatsu S; Tsujiura M; Kosuga T; Deguchi K; Konishi H; Morimura R; Shiozaki A; Fujiwara H; Okamoto K; Otsuji E
Br J Cancer; 2010 Apr; 102(9):1378-83. PubMed ID: 20389301
[TBL] [Abstract][Full Text] [Related]
10. Association between EGF promoter polymorphisms and cancer risk: a meta-analysis.
Xu W; Li Y; Wang X; Chen B; Liu S; Wang Y; Zhao W; Wu J
Med Oncol; 2010 Dec; 27(4):1389-97. PubMed ID: 20033794
[TBL] [Abstract][Full Text] [Related]
11. EGFR pathway polymorphisms and bladder cancer susceptibility and prognosis.
Mason RA; Morlock EV; Karagas MR; Kelsey KT; Marsit CJ; Schned AR; Andrew AS
Carcinogenesis; 2009 Jul; 30(7):1155-60. PubMed ID: 19372140
[TBL] [Abstract][Full Text] [Related]
12. Common genetic variability in ESR1 and EGF in relation to endometrial cancer risk and survival.
Einarsdóttir K; Darabi H; Czene K; Li Y; Low YL; Li YQ; Bonnard C; Wedrén S; Liu ET; Hall P; Liu J; Humphreys K
Br J Cancer; 2009 Apr; 100(8):1358-64. PubMed ID: 19319135
[TBL] [Abstract][Full Text] [Related]
13. Role of BCL2 (ala43thr), CCND1 (G870A) and FAS (A-670G) polymorphisms in modulating the risk of developing esophageal cancer.
Jain M; Kumar S; Lal P; Tiwari A; Ghoshal UC; Mittal B
Cancer Detect Prev; 2007; 31(3):225-32. PubMed ID: 17561354
[TBL] [Abstract][Full Text] [Related]
14. Interaction of EGFR 497Arg>Lys with EGF +61A>G polymorphism: modulation of risk in esophageal cancer.
Upadhyay R; Jain M; Kumar S; Ghoshal UC; Mittal B
Oncol Res; 2008; 17(4):167-74. PubMed ID: 18773861
[TBL] [Abstract][Full Text] [Related]
15. Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab.
Zhang W; Gordon M; Press OA; Rhodes K; Vallböhmer D; Yang DY; Park D; Fazzone W; Schultheis A; Sherrod AE; Iqbal S; Groshen S; Lenz HJ
Pharmacogenet Genomics; 2006 Jul; 16(7):475-83. PubMed ID: 16788380
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer.
Dahan L; Norguet E; Etienne-Grimaldi MC; Formento JL; Gasmi M; Nanni I; Gaudart J; Garcia S; Ouafik L; Seitz JF; Milano G
BMC Cancer; 2011 Nov; 11():496. PubMed ID: 22117530
[TBL] [Abstract][Full Text] [Related]
17. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma.
Sun T; Miao X; Zhang X; Tan W; Xiong P; Lin D
J Natl Cancer Inst; 2004 Jul; 96(13):1030-6. PubMed ID: 15240787
[TBL] [Abstract][Full Text] [Related]
18. Influence of apoptosis (BCL2, FAS), cell cycle (CCND1) and growth factor (EGF, EGFR) genetic polymorphisms on survival outcome: an exploratory study in squamous cell esophageal cancer.
Jain M; Kumar S; Upadhyay R; Lal P; Tiwari A; Ghoshal UC; Mittal B
Cancer Biol Ther; 2007 Oct; 6(10):1553-8. PubMed ID: 17912028
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
